Literature DB >> 11705883

Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice.

N Sato1, H Kobayashi, T Saga, Y Nakamoto, T Ishimori, K Togashi, Y Fujibayashi, J Konishi, M W Brechbiel.   

Abstract

To establish an effective nonviral gene delivery and a corresponding imaging method for i.p.-disseminated tumors, various oligonucleotide-carrier complexes were synthesized, and their in vitro and in vivo properties were examined. The 20-mer multiamino-linked oligonucleotide (oligo), synthesized as antisense against the c-erbB-2 sequence, and the 3'-biotinylated form of the same oligonucleotide (oligo-Bt) were (111)In labeled through a diethylenetriaminepentaacetic acid chelate. (111)In-oligo was mixed with generation 4 polyamidoamine dendrimer (G4) or with biotinylated G4 (G4-Bt), which are positively charged to form electrostatic complexes. (111)In-oligo/G4-Bt and (111)In-oligo-Bt were conjugated to avidin ((111)In-oligo/G4-Av and (111)In-oligo-Av, respectively). (111)In-oligo/G4, (111)In-oligo/G4-Av, (111)In-oligo-Av, and carrier-free (111)In-oligo (2.96 kBq/22.4-45.9 ng of oligo) were examined for internalization in vitro in human ovarian cancer cells (SHIN3). Biodistribution of (111)In-oligo-carrier complexes or (111)In-oligo was examined in normal (n = 4-7) or i.p. SHIN3 tumor-bearing (n = 6-10) mice 2-24 h after i.p. injection (74 kBq/125-300 ng). Scintigraphy of i.p. tumor-bearing and normal mice was performed at various times postinjection of (111)In-oligo-carrier complex or (111)In-oligo (1.85 MBq/2.2 ng). (111)In-oligo-carrier complexes bound to the tumor cells were internalized at a rate of 34-56% at 24 h. In vivo, G4, G4-Av, and Av significantly enhanced tumor delivery of (111)In-oligo [9.1, 14.5, and 24.4% of injected dose per g of tissue (ID/g) at 24 h; P < 0.05, < 0.01, and < 0.0001, respectively] compared with delivery without carrier (0.8% ID/g). Scintigrams of (111)In-oligo delivered to the i.p.-disseminated tumors by the carriers were successfully obtained. In conclusion, G4, G4-Av, and Av can effectively deliver (111)In-oligo to i.p.-disseminated tumors. (111)In-oligo-carrier complexes also have potential as tracers for imaging and monitoring of gene delivery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705883

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

Review 1.  Biologically optimized nanosized molecules and particles: more than just size.

Authors:  Michelle R Longmire; Mikako Ogawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2011-05-11       Impact factor: 4.774

Review 2.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

Review 3.  Imaging oncogene expression.

Authors:  Archana Mukherjee; Eric Wickstrom; Mathew L Thakur
Journal:  Eur J Radiol       Date:  2009-03-04       Impact factor: 3.528

4.  An enzymatically activated fluorescence probe for targeted tumor imaging.

Authors:  Mako Kamiya; Hisataka Kobayashi; Yukihiro Hama; Yoshinori Koyama; Marcelino Bernardo; Tetsuo Nagano; Peter L Choyke; Yasuteru Urano
Journal:  J Am Chem Soc       Date:  2007-03-13       Impact factor: 15.419

5.  Amino acid-functionalized dendrimers with heterobifunctional chemoselective peripheral groups for drug delivery applications.

Authors:  Raghavendra S Navath; Anupa R Menjoge; Bing Wang; Roberto Romero; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Biomacromolecules       Date:  2010-06-14       Impact factor: 6.988

6.  Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor.

Authors:  Andrew J Hollins; Mustapha Benboubetra; Yadollah Omidi; Bernd H Zinselmeyer; Andreas G Schatzlein; Ijeoma F Uchegbu; Saghir Akhtar
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

7.  In vitro detection of mdr1 mRNA in murine leukemia cells with 111In-labeled oligonucleotide.

Authors:  Jingming Bai; Kunihiko Yokoyama; Seigo Kinuya; Kazuhiro Shiba; Ryo Matsushita; Masaaki Nomura; Takatoshi Michigishi; Norihisa Tonami
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-21       Impact factor: 9.236

8.  Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents.

Authors:  Hisataka Kobayashi; Mikako Ogawa; Nobuyuki Kosaka; Peter L Choyke; Yasuteru Urano
Journal:  Nanomedicine (Lond)       Date:  2009-06       Impact factor: 5.307

Review 9.  Dendrimers in medical nanotechnology.

Authors:  Tristan Barrett; Gregory Ravizzini; Peter L Choyke; Hisataka Kobayashi
Journal:  IEEE Eng Med Biol Mag       Date:  2009 Jan-Feb

Review 10.  Targeted nanoparticles in imaging: paving the way for personalized medicine in the battle against cancer.

Authors:  Soo J Shin; Jaymes R Beech; Kimberly A Kelly
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.